December 05, 2020
Deepu Madduri, MD, assistant professor, Hematology and Medical Oncology of the Mount Sinai Hospital, Mount Sinai Beth Israel, discusses the results of the CARTITUDE-1 study, which analyzed ciltacabtagene autoleucel, a CAR-T-cell therapy with 2 B-cell maturation antigen–targeting single-domain antibodies, for the treatment of patients with relapsed/refractory multiple myeloma.
Madduri D, Berdeja J, Usmani S, et al. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma (Abstract 177). https://ash.confex.com/ash/2020/webprogram/Paper136307.html. December 5, 2020.